News

Hosted on MSN3m
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies
As competition continues to intensify in the obesity treatment market, Novo Nordisk has struck a collaboration ...
MedPage Today on MSN2d
Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
InvestorsHub on MSN15h
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments
Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...
pharmaphorum3d
More data back Zepbound over Wegovy for weight loss
"These data confirm Zepbound as a leading treatment option for people living with obesity and equip healthcare ...
STAT2d
Pharmalittle: We’re reading about Trump drug-pricing plan, obesity drug trial data, and more
President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...